litlas
ログインアカウント作成

Denise A. Yardley

2001–2025 年に発表

92
論文数
22,711
被引用数
63
h 指数
88
i10 指数

被引用数

Denise A. Yardley の年別被引用数1948 年: 被引用 1 件1964 年: 被引用 1 件1971 年: 被引用 1 件1993 年: 被引用 3 件1994 年: 被引用 1 件1999 年: 被引用 1 件2001 年: 被引用 2 件2002 年: 被引用 3 件2003 年: 被引用 11 件2004 年: 被引用 16 件2005 年: 被引用 25 件2006 年: 被引用 13 件2007 年: 被引用 13 件2008 年: 被引用 12 件2009 年: 被引用 16 件2010 年: 被引用 48 件2011 年: 被引用 99 件2012 年: 被引用 156 件2013 年: 被引用 187 件2014 年: 被引用 194 件2015 年: 被引用 220 件2016 年: 被引用 207 件2017 年: 被引用 244 件2018 年: 被引用 298 件2019 年: 被引用 799 件2020 年: 被引用 967 件2021 年: 被引用 926 件2022 年: 被引用 785 件2023 年: 被引用 669 件2024 年: 被引用 950 件2025 年: 被引用 572 件2026 年: 被引用 15 件1949〜1963 年は被引用が無いため表示していません1965〜1970 年は被引用が無いため表示していません1972〜1992 年は被引用が無いため表示していません1995〜1998 年は被引用が無いため表示していません2000 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,579 件、この内訳の 23.6%中国: 引用元論文 941 件、この内訳の 8.6%イタリア: 引用元論文 759 件、この内訳の 7%イギリス: 引用元論文 586 件、この内訳の 5.4%ドイツ: 引用元論文 531 件、この内訳の 4.9%フランス: 引用元論文 499 件、この内訳の 4.6%スペイン: 引用元論文 457 件、この内訳の 4.2%カナダ: 引用元論文 421 件、この内訳の 3.9%スイス: 引用元論文 347 件、この内訳の 3.2%日本: 引用元論文 320 件、この内訳の 2.9%ベルギー: 引用元論文 311 件、この内訳の 2.8%オーストラリア: 引用元論文 296 件、この内訳の 2.7%
0%23.6%その他 26.2%

機関

分野

  • Medicine67.9%
  • Biochemistry, Genetics and Molecular Biology25.4%
  • Materials Science1.9%
  • Immunology and Microbiology1.8%
  • Engineering0.7%
  • Computer Science0.7%
  • その他1.6%

トピック

  • Advanced Breast Cancer Therapies10.2%
  • HER2/EGFR in Cancer Research9.5%
  • Breast Cancer Treatment Studies6.9%
  • Cancer Treatment and Pharmacology4%
  • Cancer-related Molecular Pathways3.5%
  • Monoclonal and Polyclonal Antibodies Research2.7%
  • その他63.2%

共著者

全論文

検索で開く
  1. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer

    著者: Gabriel N. Hortobágyi, Salomon M. Stemmer, Howard A. Burris, Yoon Sim Yap, Gabe S. Sonke, Shani Paluch–Shimon, Mario Campone, Kimberly Blackwell, Fabrice André, Eric P. Winer, Wolfgang Janni, Sunil Verma, PierFranco Conte, Carlos L. Arteaga, David Cameron, Katarína Petráková, Lowell L. Hart, Cristian Villanueva, Arlene Chan, Erik Jakobsen, Arnd Nusch, Olga Burdaeva, Eva‐Maria Grischke, Emilio Alba, Erik Wist, Norbert Marschner, Anne Favret, Denise A. Yardley, Thomas Bachelot, Ling-Ming Tseng, Sibel Blau, Fengjuan Xuan, Farida Souami, Michelle C. Miller, Caroline Germa, Samit Hirawat, Joyce O’Shaughnessy - New England Journal of Medicine 2016 被引用: 2,009

  2. Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

    著者: José Baselga, Mario Campone, Martine Piccart, Howard A. Burris, Hope S. Rugo, Tarek Sahmoud, Shinzaburo Noguchi, Michael Gnant, Kathleen I. Pritchard, Fabienne Lebrun, J. Thaddeus Beck, Yoshinori Ito, Denise A. Yardley, Ines Deleu, Alejandra Perez, Thomas Bachelot, Luc Vittori, Zhiying Xu, Pabak Mukhopadhyay, David Lebwohl, Gabriel N. Hortobágyi - New England Journal of Medicine 2011 被引用: 2,828

  3. Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer

    著者: Gϋnter von Minckwitz, Marion Procter, Evandro de Azambuja, Dimitrios Zardavas, Mark Benyunes, Giuseppe Viale, Thomas Suter, Amal Arahmani, Nathalie Rouchet, Emma Clark, Adam Knott, István Láng, Christelle Lévy, Denise A. Yardley, José Bines, Richard D. Gelber, Martine Piccart, José Baselga - New England Journal of Medicine 2017 被引用: 1,399

  4. Ribociclib plus Endocrine Therapy in Early Breast Cancer

    著者: Dennis J. Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas P. McAndrew, Bożena Kukiełka-Budny, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock‐Ah Im, Manuel Ruíz-Borrego, Sherene Loi, Binghe Xu, Sara A. Hurvitz, Carlos H. Barrios, Michael Untch, Rebecca Moroose, F. Visco, Karen Afenjar, Rodrigo Fresco, Irene Severin, Yan Ji, Farhat Ghaznawi, Zheng Li, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Gabriel N. Hortobágyi - New England Journal of Medicine 2024 被引用: 357

  5. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

    著者: Otto Metzger, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell’Orto, Leila Russo, Tari A. King, Kornélia Polyák, Franziska Michor, Eric P. Winer, Ian E. Krop - Cancer Discovery 2021 被引用: 240

  6. LBA20 A randomized, double-blind trial of nivolumab (NIVO) vs placebo (PBO) with neoadjuvant chemotherapy (NACT) followed by adjuvant endocrine therapy (ET) ± NIVO in patients (pts) with high-risk, ER+ HER2− primary breast cancer (BC)

    著者: Sherene Loi, Giuseppe Curigliano, Roberto Salgado, Roberto Iván Romero Díaz, Suzette Delaloge, C. Rojas, Marleen Kok, C. Saura Manich, Nadia Harbeck, Elizabeth A. Mittendorf, Denise A. Yardley, Lajos Pusztai, Alberto Suárez Zaizar, Aurelian Ungureanu, Felipe Ades, R. Chandra, Raheel Nathani, Misena Pacius, Jintong Wu, Heather L. McArthur - Annals of Oncology 2023 被引用: 103

  7. MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2− Metastatic Breast Cancer

    著者: Maura N. Dickler, Sara M. Tolaney, Hope S. Rugo, Javier Cortés, Véronique Dièras, Debra A. Patt, Hans Wildiers, Clifford A. Hudis, Joyce O’Shaughnessy, Esther Zamora, Denise A. Yardley, Martin Frenzel, Andrew Koustenis, José Baselga - Clinical Cancer Research 2017 被引用: 683

  8. Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial

    著者: Sara M. Tolaney, Paolo Tarantino, Noah Graham, Nabihah Tayob, Laia Paré, Guillermo Villacampa, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Romualdo Barroso‐Sousa, Patricia Villagrasa, Michelle K. DeMeo, Molly DiLullo, Jorge Gómez Tejeda Zañudo, Jakob Weiß, Nikhil Wagle, Ann H. Partridge, Adrienne G. Waks, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Aleix Prat, Eric P. Winer - The Lancet Oncology 2023 被引用: 165

  9. Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial

    著者: Charles E. Geyer, William M. Sikov, Jens Huober, Hope S. Rugo, Norman Wolmark, J. O’Shaughnessy, David Maag, Michael Untch, Mehra Golshan, José Ponce, Otto Metzger, Martin Dunbar, W. Fraser Symmans, Priya Rastogi, Joohyuk Sohn, Robyn R. Young, Gail S. Wright, C. Harkness, Kristi McIntyre, Denise A. Yardley, Sibylle Loibl - Annals of Oncology 2022 被引用: 219

  10. Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

    著者: Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, Javier Cortés, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Christelle Lévy, Ursa Brown‐Glaberman, Jean-­Marc Ferrero, Maaike de Boer, Sung‐Bae Kim, Katarína Petráková, Denise A. Yardley, Orit Freedman, Erik Jakobsen, Bella Kaufman, Rinat Yerushalmi, Peter A. Fasching, Jeffrey L. Nordstrom, Ezio Bonvini, Scott Koenig, Sutton Edlich, Shengyan Hong, Edwin P. Rock, William J. Gradishar, SOPHIA Study Group - JAMA Oncology 2021 被引用: 349

  11. nab-Paclitaxel mechanisms of action and delivery

    著者: Denise A. Yardley - Journal of Controlled Release 2013 被引用: 496

  12. Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer

    著者: Tiffany A. Traina, Kathy D. Miller, Denise A. Yardley, Janice F. Eakle, Lee S. Schwartzberg, Joyce O’Shaughnessy, William J. Gradishar, Peter Schmid, Eric P. Winer, Catherine M. Kelly, Rita Nanda, Ayca Gucalp, Ahmad Awada, Laura García‐Estévez, Maureen Trudeau, Joyce Steinberg, Hirdesh Uppal, Iulia Cristina Tudor, Amy Peterson, Javier Cortés - Journal of Clinical Oncology 2018 被引用: 519

  13. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2- early breast cancer: Primary results from the phase III NATALEE trial.

    著者: Dennis J. Slamon, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock‐Ah Im, Miguel Martín, Sherene Loi, Binghe Xu, Sara A. Hurvitz, Carlos H. Barrios, Michael Untch, Rebecca Moroose, Fran Visco, Rodrigo Fresco, Tetiana Taran, Gabriel N. Hortobágyi - Journal of Clinical Oncology 2023 被引用: 139

  14. Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

    著者: Denise A. Yardley, Shinzaburo Noguchi, Kathleen I. Pritchard, Howard A. Burris, José Baselga, Michael Gnant, Gabriel N. Hortobágyi, Mario Campone, Barbara Pistilli, Martine Piccart, Bohuslav Melichar, Katarína Petráková, Francis P. Arena, Frans Erdkamp, Wael A. Harb, Wentao Feng, Ayelet Cahana, Tetiana Taran, David Lebwohl, Hope S. Rugo - Advances in Therapy 2013 被引用: 520

  15. A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast Cancer

    著者: Sara M. Tolaney, Solmaz Sahebjam, Émilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise A. Yardley, Arlene Chan, PierFranco Conte, Véronique Dièras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen, Carey K. Anders - Clinical Cancer Research 2020 被引用: 198

  16. Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer

    著者: Dennis J. Slamon, Peter A. Fasching, Sara A. Hurvitz, Stephen Chia, John Crown, Miguel Martín, Carlos H. Barrios, Aditya Bardia, Seock‐Ah Im, Denise A. Yardley, Michael Untch, Chiun‐Sheng Huang, Daniil Stroyakovskiy, Binghe Xu, Rebecca Moroose, Sherene Loi, F. Visco, Valerie Bee-Munteanu, Karen Afenjar, Rodrigo Fresco, Tetiana Taran, Arunava Chakravartty, Juan Pablo Zarate, Agnes Lteif, Gabriel N. Hortobágyi - Therapeutic Advances in Medical Oncology 2023 被引用: 99

  17. Denosumab Compared With Zoledronic Acid for the Treatment of Bone Metastases in Patients With Advanced Breast Cancer: A Randomized, Double-Blind Study

    著者: Alison Stopeck, Allan Lipton, Jean-Jacques Body, Guenther G. Steger, Katia Tonkin, Richard H. De Boer, Mikhail Lichinitser, Yasuhiro Fujiwara, Denise A. Yardley, María Eugenia Ibarrarán Viniegra, Michelle Fan, Qi Jiang, Roger Dansey, Susie Jun, Ada Braun - Journal of Clinical Oncology 2010 被引用: 1,593

  18. Phase I/II Trial of Exemestane, Ribociclib, and Everolimus in Women with HR+/HER2− Advanced Breast Cancer after Progression on CDK4/6 Inhibitors (TRINITI-1)

    著者: Aditya Bardia, Sara A. Hurvitz, Angela DeMichele, Amy S. Clark, Amelia Zelnak, Denise A. Yardley, Meghan Karuturi, Tara Sanft, Sibel Blau, Lowell L. Hart, X. Cynthia, Hope S. Rugo, Das Purkayastha, Stacy Moulder - Clinical Cancer Research 2021 被引用: 113

  19. Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial

    著者: Hope S. Rugo, Seock‐Ah Im, Fátima Cardoso, Javier Cortés, Giuseppe Curigliano, Antonino Musolino, Mark D. Pegram, Thomas Bachelot, Gail S. Wright, Cristina Saura, Santiago Escrivá-de-Romaní, Michelino De Laurentiis, Gary N. Schwartz, Timothy Pluard, Francesco Ricci, William R. Gwin, Christelle Lévy, Ursa Brown‐Glaberman, Jean-­Marc Ferrero, Maaike de Boer, Sung‐Bae Kim, Katarína Petráková, Denise A. Yardley, Orit Freedman, Erik Jakobsen, Einav Nili Gal‐Yam, Rinat Yerushalmi, Peter A. Fasching, Peter A. Kaufman, Emily J. Ashley, Raul Perez-Olle, Shengyan Hong, Minori Koshiji Rosales, William J. Gradishar, on behalf of the SOPHIA Study Group - Journal of Clinical Oncology 2022 被引用: 80

  20. A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

    著者: Lori J. Goldstein, Raymond P. Perez, Denise A. Yardley, Linda K. Han, James M. Reuben, Hui Gao, Susan McCanna, Beth Butler, Pier Adelchi Ruffini, Yi Liu, Roberto R. Rosato, Jenny C. Chang - Breast Cancer Research 2020 被引用: 137

  21. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer

    著者: Nicholas J. Robert, Véronique Dièras, John A. Glaspy, Adam Brufsky, Igor Bondarenko, Oleg Lipatov, Edith A. Perez, Denise A. Yardley, Stephen Chan, Xian Zhou, S. Phan, Joyce O’Shaughnessy - Journal of Clinical Oncology 2011 被引用: 1,061

  22. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

    著者: Sara M. Tolaney, William T. Barry, Chau T. Dang, Denise A. Yardley, Beverly Moy, P. Kelly Marcom, Kathy S. Albain, Hope S. Rugo, Matthew J. Ellis, Iuliana Shapira, Antonio C. Wolff, Lisa A. Carey, Beth Overmoyer, Ann H. Partridge, Hao Guo, Clifford A. Hudis, Ian E. Krop, Harold J. Burstein, Eric P. Winer - New England Journal of Medicine 2015 被引用: 748

  23. Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

    著者: Ian E. Krop, Ingrid A. Mayer, Vinod Ganju, Maura N. Dickler, Stephen Johnston, Serafín Morales, Denise A. Yardley, Bohuslav Melichar, Andres Forero‐Torres, Soo Chin Lee, Richard de Boer, Katarína Petráková, Susanne Vallentin, Edith A. Perez, Martine Piccart, Matthew J. Ellis, Eric P. Winer, Steven Gendreau, Mika K. Derynck, Mark R. Lackner, Gallia G. Levy, Jiaheng Qiu, Jing He, Peter Schmid - The Lancet Oncology 2016 被引用: 295

  24. Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial

    著者: Sara M. Tolaney, Nabihah Tayob, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose, Jiani Hu, Douglas Weckstein, Antonio C. Wolff, Katherine E. Reeder‐Hayes, Hope S. Rugo, Bhuvaneswari Ramaswamy, Dan Sayam Zuckerman, Lowell L. Hart, Vijayakrishna K. Gadi, Michael Constantine, Kit Cheng, Frederick Briccetti, Bryan P. Schneider, Audrey Merrill Garrett, Kelly Marcom, Kathy S. Albain, Patricia DeFusco, Nadine Tung, Blair Ardman, Rita Nanda, Rachel C. Jankowitz, Mothaffar F. Rimawi, Vandana G. Abramson, Paula R. Pohlmann, Catherine Van Poznak, Andres Forero‐Torres, Minetta C. Liu, Kathryn J. Ruddy, Yue Zheng, Shoshana M. Rosenberg, Richard D. Gelber, Lorenzo Trippa, William T. Barry, Michelle K. DeMeo, Harold J. Burstein, Ann H. Partridge, Eric P. Winer, Ian E. Krop - Journal of Clinical Oncology 2021 被引用: 139